EGFR and non-small cell lung carcinoma: Prospective clinical trials of first- or second-generation (1st or 2nd) epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for treatment of patients with non-small cell lung cancer (NSCLC) harboring EGFR mutations have demonstrated remarkable response rates of approximately 70%1, 2, 3, 4, 5, 6, 7.